Breaking
🌏 NMPA
Sun Pharma Organon Partnership to Expand Access to Key Medicines
Newswomen's health, spasticity, rheumatoid arthritisMay 4, 2026

Sun Pharma Organon Partnership to Expand Access to Key Medicines

Sun Pharma has announced a strategic partnership with Organon to commercialize five of Organon's established products across India. This collaboration aims to leverage Sun Pharma's extensive network to improve patient access to vital treatments.

Dr. Yuna Park
UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases
NewsAutoimmune and inflammatory diseasesMay 4, 2026

UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases

UCB's $2.2B acquisition of Candid Therapeutics brings novel T-cell engager technology for autoimmune diseases, marking major expansion beyond oncology applications.

Kenji Watanabe
IMG Pharma Acquires Matsumoto Pharmaceutical in Strategic Japanese Market Expansion Deal
NewsApr 28, 2026

IMG Pharma Acquires Matsumoto Pharmaceutical in Strategic Japanese Market Expansion Deal

IMG Pharmaceutical announces definitive agreement to acquire Matsumoto Pharmaceutical, expanding its presence in Japan's pharmaceutical manufacturing market.

Kenji Watanabe
BioMarin Completes $3 Billion Acquisition of Amicus Therapeutics, Expands Rare Disease Portfolio with Galafold and Pompe Therapies
NewsRare genetic diseases (lysosomal storage disorders)Apr 28, 2026

BioMarin Completes $3 Billion Acquisition of Amicus Therapeutics, Expands Rare Disease Portfolio with Galafold and Pompe Therapies

BioMarin's acquisition of Amicus adds globally approved Galafold for Fabry disease and POMBILITI/OPFOLDA combination for Pompe disease to its rare disease pipeline.

Dr. Yuna Park